Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNR002
MIFTS: 51

Bone Resorption Disease

Categories: Bone diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Resorption Disease

About this section

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 12 15
Bone Resorption 44

Classifications:

MalaCards categories:
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080011
MeSH 44 D001862
Sources

Summaries for Bone Resorption Disease

About this section
Disease Ontology : 12 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary : Bone Resorption Disease, also known as bone resorption, is related to osteopetrosis and bone giant cell tumor. An important gene associated with Bone Resorption Disease is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs Isosorbide Dinitrate and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and bone marrow, and related phenotypes are cellular and growth/size/body region

Wikipedia : 75 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Sources

Related Diseases for Bone Resorption Disease

About this section

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 osteopetrosis 33.2 TNFSF11 TNFRSF11A LRP5 CTSK
2 bone giant cell tumor 33.1 TNFSF11 CTSK CALCA ACP5
3 paget's disease of bone 32.9 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
4 osteitis fibrosa 32.9 PTH CALCA BGLAP
5 multicentric carpotarsal osteolysis syndrome 32.9 TNFSF11 TNFRSF11B TNFRSF11A CTSK BGLAP
6 paget disease of bone 5, juvenile-onset 32.5 TNFSF11 TNFRSF11B TNFRSF11A CALCA
7 glucocorticoid-induced osteoporosis 31.9 TNFSF11 TNFRSF11B RUNX2 PTH IGF1 CALCA
8 periodontitis 31.9 TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP
9 hyperparathyroidism 31.3 VDR TNFRSF11B PTH CALCA BGLAP ACP5
10 primary hyperparathyroidism 31.3 VDR PTH CALCA BGLAP
11 hypercalcemia, infantile, 1 31.3 VDR PTH CALCA
12 osteomalacia 31.2 VDR PTH CALCA BGLAP
13 periodontitis, chronic 31.1 TNFSF11 TNFRSF11B
14 idiopathic hypercalciuria 31.1 VDR TNFSF11 BGLAP
15 osteomyelitis 31.0 TNFSF11 CTSK BMP2 ACP5
16 giant cell tumor 31.0 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCA BGLAP
17 rheumatoid arthritis 31.0 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
18 rickets 30.9 VDR PTH BGLAP
19 bone inflammation disease 30.9 TNFSF11 TNFRSF11B CTSK BGLAP ACP5
20 insulin-like growth factor i 30.8 IGF1 ESR1 BGLAP
21 periapical periodontitis 30.8 TNFSF11 TNFRSF11B TNFRSF11A ACP5
22 osteonecrosis 30.8 TNFSF11 TNFRSF11B RUNX2 PTH BMP2 BGLAP
23 ankylosis 30.7 TNFRSF11B SP7 RUNX2 BMP2 BGLAP
24 uremia 30.7 VDR TNFRSF11B PTH
25 renal osteodystrophy 30.7 VDR TNFRSF11B SOST PTH CALCA BGLAP
26 hypervitaminosis d 30.7 VDR PTH
27 sclerosteosis 30.7 VDR SOST RUNX2 LRP5
28 bone cancer 30.7 TNFSF11 TNFRSF11A ESR1
29 multicentric reticulohistiocytosis 30.7 TNFSF11 TNFRSF11B
30 hemophilic arthropathy 30.6 TNFSF11 TNFRSF11B TNFRSF11A
31 endosteal hyperostosis, autosomal dominant 30.6 TNFSF11 TNFRSF11B LRP5 CTSK BMP2
32 camurati-engelmann disease 30.6 LRP5 BGLAP ACP5
33 root resorption 30.6 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 CTSK CALCA
34 fibrous dysplasia 30.5 IGF1 CALCA BGLAP
35 osteogenesis imperfecta, type i 30.5 TNFRSF11B IGF1 BGLAP
36 hyperphosphatemia 30.5 VDR RUNX2 PTH
37 breast adenocarcinoma 30.3 TNFSF11 ESR1 CTSK CALCA
38 secondary hyperparathyroidism of renal origin 30.1 VDR TNFRSF11B PTH CALCA BGLAP ACP5
39 calciphylaxis 29.8 VDR PTH
40 osteoporosis 29.4 VDR TNFSF11 TNFRSF11B TNFRSF11A SP7 SOST
41 bone disease 28.0 VDR TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2
42 bone remodeling disease 27.9 ZNF592 VDR TNFSF11 TNFRSF11B TNFRSF11A SP7
43 pycnodysostosis 11.5
44 hajdu-cheney syndrome 11.5
45 failure of tooth eruption, primary 11.2
46 paget disease of bone 3 11.2
47 singleton-merten syndrome 1 11.2
48 osteopetrosis, autosomal recessive 5 11.2
49 paget disease of bone 2, early-onset 11.2
50 osteopetrosis, autosomal dominant 1 11.2

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease
Sources

Symptoms & Phenotypes for Bone Resorption Disease

About this section

MGI Mouse Phenotypes related to Bone Resorption Disease:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
2 growth/size/body region MP:0005378 10.33 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
3 homeostasis/metabolism MP:0005376 10.25 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
4 cardiovascular system MP:0005385 10.24 BMP2 ESR1 IGF1 LRP5 NFATC1 PTH
5 craniofacial MP:0005382 10.21 BMP2 CTSK LRP5 NFATC1 PTH RUNX2
6 hematopoietic system MP:0005397 10.21 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
7 immune system MP:0005387 10.18 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
8 endocrine/exocrine gland MP:0005379 10.13 CTSK ESR1 IGF1 LRP5 PTH RUNX2
9 limbs/digits/tail MP:0005371 10.13 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
10 digestive/alimentary MP:0005381 10.1 BMP2 CTSK ESR1 NFATC1 RUNX2 SLC51A
11 mortality/aging MP:0010768 9.97 BMP2 ESR1 IGF1 LRP5 NFATC1 PTH
12 integument MP:0010771 9.92 ESR1 IGF1 NFATC1 RPL24 RUNX2 TNFRSF11A
13 respiratory system MP:0005388 9.56 CTSK ESR1 IGF1 NFATC1 RUNX2 SP7
14 skeleton MP:0005390 9.5 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
Sources

Drugs & Therapeutics for Bone Resorption Disease

About this section

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
2
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
3 sodium fluoride Approved Phase 4 7681-49-4
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Pamidronate Approved Phase 4 40391-99-9 4674
7
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
10
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Pentetic acid Approved Phase 4 67-43-6
13
Turmeric Approved, Experimental, Investigational Phase 4
14
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
15
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
16
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
17
Liraglutide Approved Phase 4 204656-20-2 44147092
18
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
19
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
20
Adalimumab Approved Phase 4 331731-18-1 16219006
21
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
22
Sodium citrate Approved, Investigational Phase 4 68-04-2
23
Cinacalcet Approved Phase 4 226256-56-0 156419
24
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
25
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
26
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
27
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
28
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
29
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
30
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
31
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
33
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
36
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
37
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
38
gastric inhibitory polypeptide Investigational Phase 4 100040-31-1
39 Nitric Oxide Donors Phase 4
40 isosorbide-5-mononitrate Phase 4
41 Listerine Phase 4
42 Ibandronic Acid Phase 4
43 calcium channel blockers Phase 4
44 Estrogens Phase 4
45 Selective Estrogen Receptor Modulators Phase 4
46 Estrogen Receptor Modulators Phase 4
47 Estrogen Receptor Antagonists Phase 4
48 Raloxifene Hydrochloride Phase 4
49 Estrogen Antagonists Phase 4
50 Anti-Retroviral Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 462)
# Name Status NCT ID Phase Drugs
1 Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing) Unknown status NCT00180206 Phase 4
2 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
3 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
4 Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
5 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
6 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial Completed NCT02760979 Phase 4 Denosumab;Placebo
7 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
8 Periprosthetic Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components Completed NCT00957970 Phase 4
9 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
10 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
11 Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study Completed NCT02303873 Phase 4 Alendronate
12 Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
13 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
14 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
15 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
16 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
17 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
18 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
19 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
20 "Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects" - A Clinico Radiological Study Completed NCT03009097 Phase 4 DFDBA with atorvastatin
21 Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy Completed NCT01535027 Phase 4 teriparatide;teriparatide and raloxifene;teriparatide and alendronate
22 Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women Completed NCT00440375 Phase 4 Rosiglitazone
23 Curcumin-Simvastatin Release Profile in the Gingival Crevicular Fluid Following EDTA Root Surface Etching in the Surgical Treatment of Intrabony Periodontal Defects - A Biochemical and Clinical Study Completed NCT04044417 Phase 4 curcumin simvastatin paste;EDTA root conditioning
24 Socket Augmentation Using Different Platelet Concentrates, Atorvastatin Gel or Combination (Clinical and Histomorphometric Study) Completed NCT03231137 Phase 4 ATV gel
25 Socket Augmentation Using Atorvastatin With Or Without PRGF Derived Fibrin Scaffold (Clinical and Histomorphometric Study) Completed NCT03228771 Phase 4 PRGF/ATV;ATV gel
26 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
27 A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy Completed NCT00346697 Phase 4 Omega-3 fatty acid administration;Placebo
28 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients Completed NCT01647282 Phase 4 locally-applied minocycline HCl (1 mg)
29 The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function Completed NCT02473809 Phase 4 Liraglutide;Placebo
30 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
31 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
32 The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Completed NCT00006180 Phase 4 Alendronate
33 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
34 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
35 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
36 Treatment of Vitamin D Insufficiency Completed NCT00933244 Phase 4
37 Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial. Completed NCT03368430 Phase 4 Placebo
38 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
39 A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning Recruiting NCT03089619 Phase 4 Human-Spongiosa
40 Bone Resorption, Osteoclastogenesis and Adalimumab Recruiting NCT02035800 Phase 4 Adalimumab
41 Department of Orthopedics, National Taiwan University Hospital Recruiting NCT03868033 Phase 4 Zoledronic Acid;Denosumab
42 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
43 Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis Active, not recruiting NCT03087851 Phase 4 Zoledronic Acid
44 The Effect Of Hyaluronic Acid And Melatonin With Systemic Administration of Vitamin C On Implant Stability After Immediate Implant Placement in Anterior and Premolar Region in Systemically Healthy Patients Not yet recruiting NCT03804177 Phase 4
45 The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries Not yet recruiting NCT03812991 Phase 4 Miacalcin Calcitonin Salmon Nasal Spray
46 The Effect of Hyaluronic Acid on Implant Stability After Immediate Implant Placement in Anterior and Premolar Region in Systemically Healthy Patients Not yet recruiting NCT03691467 Phase 4 Hyaluronic Acid
47 Clinical Evaluation of Topical Melatonin Application on Implant Stability of Immediate Dental Implant in Anterior & Premolar Region in Systemically Healthy Patients (Randomized Clinical Trial) Not yet recruiting NCT03689998 Phase 4
48 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Not yet recruiting NCT03926377 Phase 4
49 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Not yet recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo
50 Assessment of Implant Stability in Immediate Post-extraction Implants With and Without the Application of Hyaluronic Acid and Melatonin Mixture: Randomized Clinical Trial Not yet recruiting NCT03692026 Phase 4 Hyaluronic acid and Melatonin Mixture

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Sources

Genetic Tests for Bone Resorption Disease

About this section
Sources

Anatomical Context for Bone Resorption Disease

About this section

MalaCards organs/tissues related to Bone Resorption Disease:

41
Bone, Breast, Bone Marrow, Prostate, Monocytes, T Cells, Kidney
Sources

Publications for Bone Resorption Disease

About this section

Articles related to Bone Resorption Disease:

(show top 50) (show all 24072)
# Title Authors PMID Year
1
Role of the captured retroviral envelope syncytin-B gene in the fusion of osteoclast and giant cell precursors and in bone resorption, analyzed ex vivo and in vivo in syncytin-B knockout mice. 38
31360740 2019
2
Multiple brain abscesses treated by extraction of the maxillary molars with chronic apical lesion to remove the source of infection. 38
31321221 2019
3
Gradient fluid shear stress regulates migration of osteoclast precursors. 38
31131719 2019
4
Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study. 38
30915317 2019
5
LY411575, a potent γ-secretase inhibitor, suppresses osteoclastogenesis in vitro and LPS-induced calvarial osteolysis in vivo. 38
31020651 2019
6
Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan. 38
30949254 2019
7
The effects of myokines on osteoclasts and osteoblasts. 38
31395341 2019
8
Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling. 38
31238089 2019
9
Molecular tools for preventing and improving diagnosis of peri-implant diseases. 38
31407432 2019
10
Concepts for prevention of complications in implant therapy. 38
31407435 2019
11
Efficacy of injectable platelet-rich plasma in reducing alveolar bone resorption following rapid maxillary expansion: A cone-beam computed tomography assessment in a randomized split-mouth controlled trial. 38
30920874 2019
12
Female-Specific Role of Progranulin to Suppress Bone Formation. 38
31237618 2019
13
Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo. 38
31211955 2019
14
Oleanolic acid inhibits RANKL-induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells. 38
31176167 2019
15
CircRNA_28313/miR-195a/CSF1 axis modulates osteoclast differentiation to affect OVX-induced bone absorption in mice. 38
31204558 2019
16
Boosting mesenchymal stem cells regenerative activities on biopolymers-calcium phosphate functionalized collagen membrane. 38
31226642 2019
17
Postnatal Runx2 deletion leads to low bone mass and adipocyte accumulation in mice bone tissues. 38
31300199 2019
18
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. 38
30955181 2019
19
Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats. 38
31410111 2019
20
Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. 38
31323222 2019
21
Eldecalcitol effects on osteoblastic differentiation and function in the presence or absence of osteoclastic bone resorption. 38
31410166 2019
22
Retrospective Chronologic Computed Tomography Analysis of Bone Flap Fusion and Resorption After Craniotomy and Autologous Cryopreserved Cranioplasty. 38
31229749 2019
23
Metabolic bone disease of prematurity: causes, recognition, prevention, treatment and long-term consequences. 38
31079069 2019
24
Assessment of finite element models for prediction of osteoporotic fracture. 38
31151004 2019
25
Osthole inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by RANKL. 38
31081953 2019
26
Horizontal ridge augmentation using xenogenous bone graft-systematic review. 38
31089897 2019
27
Assessment of condylar changes after orthognathic surgery using computed tomography regional superimposition. 38
30871846 2019
28
The accuracy of CBCT for the detection and diagnosis of vertical root fractures in vivo. 38
30861149 2019
29
Magnesium lithospermate B inhibits titanium particles-induced osteoclast formation by c-fos and inhibiting NFATc1 expression. 38
30909748 2019
30
A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model. 38
31176015 2019
31
The LunHab project: Muscle and bone alterations in male participants following a 10 day lunar habitat simulation. 38
31273869 2019
32
[Inhibition of CD4(+)T cell infiltration by interleukin-10 competent B cells in periodontitis tissues]. 38
31378035 2019
33
Facial aging trajectories: A common shape pattern in male and female faces is disrupted after menopause. 38
31189026 2019
34
Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study. 38
31227287 2019
35
LncRNA AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of retinal pigment epithelial cells by downregulating miR-383. 38
31391356 2019
36
High-Resolution Computed Tomography of the Inner Ear: Effect of Otosclerosis on Cochlear Aqueduct Dimensions. 38
30971097 2019
37
Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis. 38
30889272 2019
38
Bone alterations in inflammatory bowel diseases. 38
31423424 2019
39
Effects of buccal thickness augmentation on bone remodeling after maxillary anterior implantation. 38
31396806 2019
40
Efficacy of vitamin D plus calcium with/without alendronate on bone metabolism in immunologic thrombocytopenic purpura patients with steroid treatment: Nine-month results of a randomized, double-blinded, controlled trial. 38
31363377 2019
41
Clinical and radiographic outcomes of allogeneic block grafts for maxillary lateral ridge augmentation: A randomized clinical trial. 38
31419002 2019
42
Consumption of Very Low Mineral Water Is Associated with Lower Bone Mineral Content in Children. 38
31373351 2019
43
Knockdown of DANCR reduces osteoclastogenesis and root resorption induced by compression force via Jagged1. 38
31213122 2019
44
Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat. 38
31399090 2019
45
Cone-Beam Computed Tomography Evaluation of the Submandibular Fossa in a Group of Dental Implant Patients. 38
31344015 2019
46
Explanation for different behavior of peripheral and central giant cell granuloma by CD44 and CD34 immunostaining. 38
31433127 2019
47
Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways. 38
30815894 2019
48
The role of the musculoskeletal system in post-burn hypermetabolism. 38
31181216 2019
49
FKBP12: A partner of Snx10 required for vesicular trafficking in osteoclasts. 38
30887568 2019
50
Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. 38
31400472 2019
Sources

Variations for Bone Resorption Disease

About this section
Sources

Expression for Bone Resorption Disease

About this section
Search GEO for disease gene expression data for Bone Resorption Disease.
Sources

Pathways for Bone Resorption Disease

About this section

Pathways related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
RANK Signaling in Osteoclasts 64
Show member pathways
 12.28 TNFSF11 TNFRSF11B TNFRSF11A NFATC1 CTSK ACP5
2
Osteoclast differentiation 37
11.95 TNFSF11 TNFRSF11B TNFRSF11A NFATC1 CTSK ACP5
3
Parathyroid hormone synthesis, secretion and action 37
11.73 VDR TNFSF11 SOST RUNX2 PTH LRP5
4
Rheumatoid arthritis 37
11.7 TNFSF11 TNFRSF11A CTSK ACP5
5
Regulation of nuclear SMAD2/3 signaling 1
11.56 VDR RUNX2 ESR1
6
Endochondral Ossification 1
11.45 RUNX2 PTH IGF1
7
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.25 VDR TNFSF11 RUNX2 PTH BGLAP
8
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.93 VDR TNFSF11 TNFRSF11B TNFRSF11A RUNX2 PTH
9
Osteoblast Signaling 1
10.77 TNFSF11 TNFRSF11B PTH BGLAP
10
Drug Induction of Bile Acid Pathway 1
10.74 VDR SLC51A
11
Osteoclast Signaling 1
10.56 TNFSF11 TNFRSF11B TNFRSF11A CTSK ACP5
12
Vitamin D Metabolism 1
10.48 VDR PTH
Sources

GO Terms for Bone Resorption Disease

About this section

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNFSF11 TNFRSF11B SOST PTH IGF1 CTSK
2 extracellular space GO:0005615 9.28 TNFSF11 TNFRSF11B SOST PTH IGF1 CTSK

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 VDR TNFSF11 RUNX2 IGF1 BMP2
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 VDR TNFSF11 SP7 RUNX2 PTH NFATC1
3 cell-cell signaling GO:0007267 9.91 TNFRSF11A PTH CALCA BMP2
4 positive regulation of transcription, DNA-templated GO:0045893 9.91 SOST RUNX2 NFATC1 LRP5 IGF1 ESR1
5 animal organ morphogenesis GO:0009887 9.83 VDR TNFSF11 BMP2
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.82 TNFSF11 TNFRSF11A ESR1
7 osteoblast differentiation GO:0001649 9.8 SP7 RUNX2 BMP2 BGLAP
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.77 TNFSF11 TNFRSF11B TNFRSF11A
9 response to estrogen GO:0043627 9.77 TNFRSF11B ESR1 BGLAP
10 monocyte chemotaxis GO:0002548 9.72 TNFSF11 TNFRSF11A CALCA
11 positive regulation of bone resorption GO:0045780 9.65 TNFSF11 TNFRSF11A
12 positive regulation of glycogen biosynthetic process GO:0045725 9.64 PTH IGF1
13 cellular calcium ion homeostasis GO:0006874 9.63 VDR PTH
14 regulation of osteoclast differentiation GO:0045670 9.63 TNFSF11 BGLAP
15 positive regulation of ossification GO:0045778 9.62 PTH BMP2
16 response to inorganic substance GO:0010035 9.62 TNFRSF11B BGLAP
17 positive regulation of osteoblast differentiation GO:0045669 9.62 RUNX2 LRP5 IGF1 BMP2
18 negative regulation of bone resorption GO:0045779 9.61 TNFRSF11B CALCA
19 osteoblast development GO:0002076 9.61 RUNX2 LRP5 BGLAP
20 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.58 RUNX2 BMP2
21 mammary gland alveolus development GO:0060749 9.58 TNFSF11 TNFRSF11A ESR1
22 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.57 RUNX2 BMP2
23 bone mineralization involved in bone maturation GO:0035630 9.56 IGF1 BMP2
24 TNFSF11-mediated signaling pathway GO:0071847 9.54 TNFSF11 TNFRSF11A
25 bone mineralization GO:0030282 9.52 BMP2 BGLAP
26 mammary gland branching involved in pregnancy GO:0060745 9.51 VDR ESR1
27 skeletal system development GO:0001501 9.5 VDR TNFRSF11B RUNX2 PTH IGF1 BMP2
28 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.48 TNFSF11 TNFRSF11A
29 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.46 TNFSF11 TNFRSF11A
30 bone resorption GO:0045453 9.46 TNFSF11 PTH CTSK ACP5
31 ossification GO:0001503 9.17 TNFSF11 TNFRSF11A SOST RUNX2 BMP2 BGLAP

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 PTH IGF1 CALCA
Sources

Sources for Bone Resorption Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....